Daily pill helps patients lose 12% of body weight in early trial
A daily weight-loss pill has been shown to help patients lose about 12% of their body weight, according to the results of a clinical trial.
The drug, made by the American pharmaceutical company Eli Lilly, is a GLP-1 agonist – a type of medication that helps lower blood sugar levels, reduces appetite and slows digestion.
More than 3,000 people took part in the 72-week study. Those who received the highest dose – 36mg of orforglipron – lost on average 12.4% of their body weight, compared with just 0.9% of the control group.
The trial also showed other health benefits for users, including improvements to cholesterol, blood pressure and heart disease risk.
The results come after Novo Nordisk’s oral weight loss drug, which has been submitted for approval in the US, helped trial participants lose about 15% of their body weight.
Eli Lilly manufactures Mounjaro, a once-a-week injection that contains the drug tirzepatide, which is also used to help improve blood sugar in people with type 2 diabetes.
/static.texastribune.org/media/files/d9e42481081f1b142cfc1d7eeb5a79f1/0614%20NKP%20Laura%20RB%2004.jpg)
